Clinical Trial Update: A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy [Phase 2]

View source ↗

Summary

Phase 2 study of OSI-7904L in locally recurrent or metastatic head and neck cancer after failure of first-line therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• OSI-7904L (OSI-7904L)

Snippet

Sponsor: OSI Pharmaceuticals | Conditions: Locally Recurrent or Metastatic Cancer of the Head and Neck, Must Have Failed First-Line Therapy | Phase 2 | Status: COMPLETED